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Dear Editor,  
I read with interest the recent study by Yokota et al. [1] on polymerase chain reaction (PCR) tests for 
SARS-CoV-2 between nasopharyngeal swab (NPS) and saliva samples. The authors used a Bayesian 
latent-class model to simultaneously estimate the sensitivity and specificity of PCR tests along with 
the unknown prevalence in the study cohorts (contact tracing and airport screening), and reported the 
sensitivity of 86% and 92% respectively for NPS and saliva samples and over 99.9% specificity for 
both tests. They also reported high concordance between them and concluded that saliva samples can 
replace the conventional NPS. Compared with NPS, saliva tests are low-invasive and requires less 
involvement of healthcare professionals. The equivalent performance of saliva tests, also suggested in 
other studies [2–5], has a profound impact on the ongoing public health planning against COVID-19 
where efficient and safe testing protocols are of paramount importance. 
However, I noticed that the authors’ model has limitations due to the following two conditions, which 
rendered the reported sensitivity of 86% and 92% merely reflective of positive agreement rates 
(PARs) [6] between NPS and saliva tests. 
• NPS and saliva test results are assumed to be independent although the authors showed that 
their Ct values are highly correlated (with a Kendall's W [7] of 0.87). 
• The prevalence p was jointly estimated with other parameters, which caused the sensitivity 
almost solely determined by PAR in the data. 
I showed that posterior distributions of PAR obtained from the original data are in effect identical to 
those of sensitivity obtained from the full dataset; NPS: 86% (90% credible interval 77-93); saliva: 
90% (82-96) (Figure 1A). Almost identical distributions were also obtained from data excluding 
individuals testing negative for both tests (‘negative-negatives’, 1872/1924 participants); NPS: 88% 
(79-94) and saliva: 91% (83-96). These indicate that the original sensitivity estimates almost solely 
relied on individuals receiving at least one positive result (47 from contact tracing and 5 from airport 
screening data) and that the rest of the dataset was barely informative, which was caused by the latent 
variable p freely optimised reflecting PARs and the independent assumption. By using simulation, I 
also showed that, in the presence of high correlation between (hypothetical) viral loads in NPS and 
saliva samples (Pearson’s correlation 0.8), I can reproduce the observed contact tracing data and 
Kendall’s W (0.86), which nonetheless suggest lower sensitivity (62 % for NPS and 67% for saliva) 
than the original study (Figures 1B and 1C).  
These results highlight the inherent limitations of the original study relying on potentially 
intercorrelated single-point PCR tests without external validation of true infection statuses. Sensitivity 
and PAR correspond under the independence assumption, and this study estimated sensitivity based 
on that assumption. While I support the finding of concordance between NPS and saliva tests, the 
interpretation of their sensitivity estimates warrants caution. In practice, multiple factors can lead to 
viral loads of both NPS and saliva below the detectable limit, including samples taken too early or late 
in the infection course or simply of poor quality. PCR will remain to be the de facto gold-standard 
test; the possibility of a less-invasive sampling method without apparent loss in performance is an 
invaluable finding. However, any tests should be used with a proper understanding of their limitations 
in performance: e.g. how frequently and, more importantly, when they can fail, which this study was 
unfortunately not sufficient to inform. 
 
Figure 1. Posterior distributions and simulated dataset. (A) Estimated sensitivity and positive 
agreement rate (PAR) for nasopharyngeal swab (NPS) and saliva tests. Top panels: posterior 
distribution of sensitivity reproduced from the original method. Bottom panels: PARs obtained from 
only saliva-positive samples for NPS and NPS-positive samples for saliva. The histograms show 
10,000 posterior samples. (B) Simulated hypothetical viral loads in NPS and saliva samples. 
Assuming a multivariate-normal distribution with a Pearson’s correlation of 0.8, 61 samples were 
drawn and plotted. Detection limits for NPS and saliva tests were assumed to be -0.3 and -0.5, 
respectively (denoted by dashed lines) and each sample was coloured according to the test results 
(blue: both positive; green: one positive and one negative; red: both negative). Kendall’s W for 
samples with at least one positive test (viral load above the detection limit) was 0.86. (C) Simulated 
and original data in 2-by-2 tables. The simulated viral loads were classified as positive/negative 
according to the assumed detection limits. The left table: simulated data restricted to truly infected 
individuals. The middle table: overall simulated data combined with 100 true negative individuals 
(assumed to be negative for both tests). The right table: the original contact tracing data. 
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